Mesothelioma Treatment: Options and Care Planning

Mesothelioma Treatment at a Glance

How Doctors Choose a Treatment Plan

A treatment recommendation should explain why a particular option fits this patient’s disease, not simply list what is technically available. In practice, the decision usually reflects several factors considered together.

• Anatomical site: Pleural, peritoneal, pericardial, and tunica-vaginalis mesothelioma are not treated as one uniform disease.
• Disease extent: The location and distribution of disease can affect whether local treatment is feasible and which systemic approaches are considered.
• Histologic subtype: Epithelioid, sarcomatoid, and biphasic tumors can have different biology and may influence treatment recommendations.
• Overall health and performance status: Heart, lung, kidney, liver, functional status, and other medical conditions can affect treatment tolerance.
• Prior treatment: Previous chemotherapy, immunotherapy, surgery, or radiation changes the options available after progression.
• Symptoms and patient goals: Relieving symptoms, maintaining independence, controlling disease, and extending survival may carry different priorities for different people.

Treatment planning often uses information from Mesothelioma Diagnosis, Tests and Biopsy, Imaging Tests, and Mesothelioma Stages.

Treatment by Mesothelioma Site

The evidence is not equally strong across mesothelioma sites. Pleural mesothelioma has randomized phase III treatment data and pleural-specific FDA indications; peritoneal mesothelioma relies more heavily on surgical consensus and retrospective evidence; pericardial and tunica-vaginalis disease remain evidence-limited.

Pleural mesothelioma

Pleural mesothelioma is the best-studied anatomical type. Systemic therapy is central for many patients. Surgery is no longer justified simply because disease appears technically resectable; when it is considered, careful staging, histology, cardiopulmonary fitness, multidisciplinary review, and center experience are essential. Radiation and pleural procedures may be used for selected local-control or symptom-relief goals.

See Pleural Mesothelioma for the site-specific overview.

Peritoneal mesothelioma

Peritoneal mesothelioma should not simply inherit the pleural treatment pathway. For carefully selected patients, cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) may be considered at centers experienced in peritoneal surface malignancy. Systemic treatment may also be used, but the evidence base and sequencing are less established than in pleural mesothelioma.

See Peritoneal Mesothelioma.

Rare sites

Primary pericardial mesothelioma and mesothelioma of the tunica vaginalis are so rare that treatment evidence comes mainly from retrospective series and case reports. Pleural drug approvals, pleural staging systems, and pleural surgical recommendations therefore cannot be assumed to apply to these sites.

For anatomical context, see Types of Mesothelioma and Pericardial Mesothelioma.

Treatment for Pleural Mesothelioma

For pleural mesothelioma, treatment is shaped by histology, resectability, symptoms, performance status, comorbidities, and prior therapy. The 2025 ASCO guideline places systemic therapy at the center of care for many patients and sharply narrows the circumstances in which maximal surgical cytoreduction should be offered.

First-Line Systemic Therapy

First-line systemic therapy is not identical across histologic subtypes. For newly diagnosed nonepithelioid pleural mesothelioma, ASCO recommends nivolumab plus ipilimumab as the preferred first-line treatment when there is no contraindication to immunotherapy; chemotherapy alone should generally not be used in this setting unless immunotherapy is medically unsuitable. For epithelioid disease, nivolumab plus ipilimumab, platinum-pemetrexed chemotherapy, and pembrolizumab plus pemetrexed-platinum are evidence-based options, with the final choice guided by comorbidities, expected toxicities, patient preferences, and treatment goals.

Evidence Snapshot: What the Major Trials Actually Showed

Nivolumab and Ipilimumab

In October 2020, the U.S. Food and Drug Administration approved nivolumab plus ipilimumab as first-line treatment for adults with unresectable malignant pleural mesothelioma. The approval was based on the randomized phase III CheckMate 743 trial, which compared dual immune-checkpoint blockade with platinum-pemetrexed chemotherapy.

ASCO recommends nivolumab plus ipilimumab as a first-line option for newly diagnosed pleural mesothelioma and specifically recommends it as the preferred first-line treatment for nonepithelioid disease when immunotherapy is suitable. CheckMate 743 showed an overall-survival benefit in the full randomized population, with a particularly large difference in the nonepithelioid subgroup; subgroup data, however, do not predict the outcome of an individual patient.

Pembrolizumab With Pemetrexed and Platinum

On September 17, 2024, the FDA approved pembrolizumab with pemetrexed and platinum chemotherapy as first-line treatment for unresectable advanced or metastatic malignant pleural mesothelioma. The randomized KEYNOTE-483 trial showed an overall-survival benefit for the pembrolizumab-containing regimen compared with chemotherapy alone.

The FDA indication is pleural-specific: it covers first-line pembrolizumab with pemetrexed and platinum chemotherapy for unresectable advanced or metastatic malignant pleural mesothelioma. That label does not establish an FDA-approved indication for peritoneal, pericardial, or tunica-vaginalis mesothelioma.

Chemotherapy

Pemetrexed plus a platinum drug remains an established systemic option for pleural mesothelioma. Cisplatin is the historical partner, but ASCO recommends carboplatin as a substitute when cisplatin is not suitable. For selected patients with epithelioid histology, pemetrexed plus platinum with or without bevacizumab may be offered; bevacizumab requires separate assessment of bleeding, thrombotic, cardiovascular, blood-pressure, and other contraindications.

The chemotherapy discussion also changes after first-line immunotherapy. ASCO allows pemetrexed plus platinum, with or without bevacizumab, as the initial chemotherapy option after prior immunotherapy. Later-line choices depend on what has already been used and can include vinorelbine, gemcitabine with or without ramucirumab, or pemetrexed retreatment after a durable previous response. These are options for selected patients, not a fixed sequence.

Pegargiminase for Nonepithelioid Disease

Pegargiminase (ADI-PEG20) is an arginine-depleting drug studied in nonepithelioid pleural mesothelioma. ATOMIC-Meso showed a statistically significant overall-survival benefit when pegargiminase was added to pemetrexed-platinum chemotherapy. ASCO states that, for previously untreated nonepithelioid pleural mesothelioma when immunotherapy cannot be used, pegargiminase plus pemetrexed-platinum may be offered as a treatment option. Pegargiminase has FDA orphan-drug designation for mesothelioma but is not FDA-approved for that indication, so the distinction between guideline support and regulatory approval should remain explicit.

Do Biomarkers Choose the Treatment?

Biomarkers have important roles in diagnosis, hereditary-risk assessment, prognosis, and research, but they do not currently provide a single validated rule for choosing standard first-line therapy in pleural mesothelioma. ASCO specifically advises against using PD-L1 expression, tumor mutational burden, or microsatellite instability by themselves to choose chemotherapy instead of immunotherapy, or vice versa.

BAP1 and other molecular findings can be clinically important, especially when they raise hereditary-risk questions or help identify clinical-trial opportunities. At present, they should not be treated as stand-alone selectors of an approved systemic regimen.

Surgery for Pleural Mesothelioma

Pleural surgery is one of the most nuanced areas of mesothelioma care. Procedures intended to remove as much visible tumor as possible are different from symptom-directed procedures such as pleural drainage or pleurodesis.

Lung-sparing operations include pleurectomy/decortication (P/D) and extended P/D. Extrapleural pneumonectomy (EPP) removes the affected lung together with additional pleural and adjacent tissues. When maximal cytoreduction is offered, ASCO recommends lung-sparing surgery as the first choice because of lower operative and long-term risk; EPP is reserved for highly selected patients at centers of excellence.

What Current Evidence Says About Pleural Surgery

MARS 2, published in 2024, randomized 335 patients with resectable pleural mesothelioma after two cycles of platinum-pemetrexed chemotherapy to extended P/D plus further chemotherapy or chemotherapy alone. Median overall survival was 19.3 months with surgery plus chemotherapy versus 24.8 months with chemotherapy alone, and serious adverse events were substantially more frequent in the surgery group. These results directly challenge routine aggressive cytoreductive surgery based only on technical resectability.

Radiation Therapy

Radiation therapy directs high-energy treatment at a defined area. In mesothelioma, it may be used for symptom relief, selected local control, or as part of a broader multimodality plan. Its role depends on anatomy, prior treatment, treatment goals, and the ability to limit exposure to nearby healthy tissues.

Radiation therapy alone is not considered curative treatment for mesothelioma. Its most established uses are symptom relief and selected local-control or multimodality settings. ASCO also recommends against routine prophylactic irradiation of pleural intervention tracts solely to prevent tract recurrence.

Tumor Treating Fields

Tumor Treating Fields (TTFields) use low-intensity alternating electric fields delivered through transducer arrays placed on the torso. Optune Lua is authorized in the United States through an FDA Humanitarian Device Exemption for adults with unresectable, locally advanced or metastatic malignant pleural mesothelioma when used concurrently with pemetrexed and platinum-based chemotherapy.

The evidentiary limitation is important. STELLAR enrolled 80 patients in a prospective single-arm phase II study; without a randomized control group, its median survival result cannot establish the same level of comparative benefit as a phase III randomized trial. The 2025 ASCO guideline therefore found insufficient evidence to recommend for or against adding TTFields to pemetrexed-platinum chemotherapy.

Treatment for Peritoneal Mesothelioma

Peritoneal mesothelioma develops in the lining of the abdomen and requires a site-specific treatment discussion. Pleural-mesothelioma drug approvals, surgical trials, and staging pathways should not be automatically transferred to peritoneal disease.

Cytoreductive Surgery With HIPEC

For carefully selected patients, cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) may be considered at an experienced center. CRS aims to remove visible abdominal disease, and HIPEC circulates heated chemotherapy within the abdominal cavity during surgery.

Patient selection is crucial. Disease distribution, histology, performance status, operative fitness, and the likelihood of achieving meaningful cytoreduction all matter. A 2025 multisociety GRADE consensus strongly endorsed CRS-HIPEC for a carefully selected subset despite very low certainty of evidence, and the 2025/2026 U.S. consensus pathway likewise emphasizes multidisciplinary assessment and centralized expertise. That combination—strong expert consensus but limited high-quality comparative evidence—is the most accurate way to describe the current evidence base.

The optimal role and timing of systemic therapy in peritoneal mesothelioma remain less certain than the first-line systemic pathways for pleural disease. Current consensus highlights the limited data and supports clinical-trial enrollment when appropriate rather than simply importing pleural regimens as if they had site-specific randomized evidence.

Rare-Site Mesothelioma Treatment

Primary pericardial mesothelioma

Primary pericardial mesothelioma is exceptionally rare, and no randomized treatment pathway exists. Evidence comes from retrospective reviews and case reports. Surgery, systemic therapy, drainage or other symptom-directed procedures, and occasionally radiation are individualized according to disease distribution, symptoms, patient fitness, and specialist judgment. Retrospective associations with treatment outcome should not be interpreted as proof of benefit.

Mesothelioma of the tunica vaginalis

Mesothelioma of the tunica vaginalis arises from the serosal lining around the testis and is biologically distinct from typical germ-cell testicular cancer. Published evidence is dominated by case reports and case-series data. Local surgery is central in most reported management strategies, while treatment for nodal, recurrent, or metastatic disease is not standardized.

Treatment After Progression

There is no single second-line sequence for every patient with mesothelioma. The next treatment depends on which therapies were used previously, how long disease control lasted, histology, performance status, organ function, toxicity, patient priorities, and trial availability.

For pleural mesothelioma, later-line treatment depends on the first-line regimen. After prior chemotherapy, single- or double-agent immunotherapy may be offered when it has not already been used. After first-line immunotherapy, pemetrexed plus platinum with or without bevacizumab is an ASCO-supported chemotherapy option. After exposure to both immunotherapy and platinum-pemetrexed, options can include vinorelbine or gemcitabine with or without ramucirumab; oral vinorelbine and gemcitabine plus ramucirumab also have specific ASCO recommendations after progression on platinum-pemetrexed. Pemetrexed-based retreatment may be reasonable after a durable previous response of more than six months.

Clinical Trials and Emerging Approaches

Clinical trials study new drugs, new combinations, devices, surgical strategies, biomarkers, and other approaches. Eligibility depends on the specific protocol, and participation is voluntary. A trial is not guaranteed to help an individual participant.

Cell therapies, mesothelin-directed agents, metabolic strategies, novel immunotherapy combinations, and other targeted approaches remain active areas of research. Some have encouraging phase I–III data, but a positive trial signal, orphan-drug designation, or guideline discussion is not the same as an FDA-approved standard indication.

Durvalumab and the DREAM3R Trial

Durvalumab plus platinum-pemetrexed produced encouraging phase II results, but the randomized phase III DREAM3R trial did not confirm an overall-survival advantage. The study closed early because of slow accrual, and a 2026 AACR report states that the primary overall-survival endpoint was not met. For now, durvalumab is best discussed as an evolving evidence area rather than grouped with the FDA-labeled first-line pleural-mesothelioma regimens above.

For current trial listings, clinicians and patients can use the U.S. National Library of Medicine registry at ClinicalTrials.gov.

Supportive and Palliative Care

Supportive care, sometimes called palliative care, can be provided alongside disease-directed treatment. It does not mean that treatment has stopped. Its purpose is to reduce symptom burden, preserve function, and support quality of life for patients and families.

• Pain or chest/abdominal discomfort
• Breathlessness and pleural-effusion symptoms
• Fatigue and reduced activity
• Nutrition and appetite concerns
• Sleep, anxiety, mood, and coping
• Practical and caregiver support

Procedures such as drainage of pleural or abdominal fluid are primarily used to relieve symptoms or prevent recurrent fluid accumulation. They do not, by themselves, treat the underlying cancer systemically.

The Mesothelioma Care Team

Mesothelioma care often involves several specialties. Not every patient needs every specialist, and the team depends on the anatomical site and treatment plan.

• Medical oncologist: Plans and monitors systemic treatment.
• Thoracic surgeon: Assesses pleural surgical options when relevant.
• Peritoneal surgical oncologist: Evaluates CRS-HIPEC candidacy for selected peritoneal disease.
• Radiation oncologist: Plans radiation when it has a role in symptom control or multimodality treatment.
• Pulmonologist: Supports pleural procedures, lung-related symptoms, and respiratory assessment.
• Radiologist and pathologist: Provide imaging and tissue information that guide treatment decisions.
• Palliative-care team: Supports symptoms, function, communication, and quality of life.

Because mesothelioma is uncommon, a second opinion at an experienced center can be useful for complex decisions. See Find a Mesothelioma Specialist.

Preparing to Discuss Treatment

1. Bring pathology and imaging reports when available.
2. List current medicines, allergies, and major medical conditions.
3. Ask what the treatment is intended to achieve.
4. Ask why this option is being recommended over reasonable alternatives.
5. Ask about expected benefits, uncertainties, and important side effects.
6. Ask how treatment response or progression will be monitored.
7. Ask whether a specialist second opinion or clinical trial could be relevant.
8. Clarify who to contact between appointments if new symptoms develop.

Questions to Ask Your Medical Team

1. What is the goal of the recommended treatment in my situation?
2. Which options are supported by evidence for my anatomical type and histology?
3. How does the extent of disease affect the plan?
4. What are the most important benefits, risks, and uncertainties?
5. What would make surgery appropriate or inappropriate for me?
6. If immunotherapy is considered, which symptoms should I report urgently?
7. If chemotherapy is considered, why is cisplatin or carboplatin being recommended?
8. Would Tumor Treating Fields apply to my specific pleural-mesothelioma situation?
9. If I have peritoneal mesothelioma, should I be evaluated at a center that performs CRS-HIPEC?
10. What options could be considered if the first treatment stops controlling the disease?
11. Are there clinical trials that match my situation?
12. What supportive-care services are available during active treatment?

Frequently Asked Questions

References

1. PDQ® Adult Treatment Editorial Board. Malignant Mesothelioma Treatment (PDQ®). National Cancer Institute. Updated May 12, 2025. PMID: 26389420. View source.
2. Kindler HL, Ismaila N, Bazhenova L, et al. Treatment of Pleural Mesothelioma: ASCO Guideline Update. Journal of Clinical Oncology. 2025;43(8):1006–1038. PMID: 39778125. doi:10.1200/JCO-24-02425.
3. Baas P, Scherpereel A, Nowak AK, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021;397(10272):375–386. PMID: 33485464. doi:10.1016/S0140-6736(20)32714-8.
4. Chu Q, Perrone F, Greillier L, et al. Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial. Lancet. 2023;402(10419):2295–2306. PMID: 37931632. doi:10.1016/S0140-6736(23)01613-6.
5. U.S. Food and Drug Administration. FDA approves pembrolizumab with chemotherapy for unresectable advanced or metastatic malignant pleural mesothelioma. September 17, 2024. View source.
6. Lim E, Waller D, Lau K, et al. Extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (MARS 2): a phase 3 randomised controlled trial. Lancet Respir Med. 2024;12(6):457–466. PMID: 38740044. doi:10.1016/S2213-2600(24)00119-X.
7. U.S. Food and Drug Administration. Humanitarian Device Exemption H180002: Optune Lua. Original decision date May 23, 2019. View source.
8. Ceresoli GL, Aerts JG, Dziadziuszko R, et al. Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial. Lancet Oncology. 2019;20(12):1702–1709. PMID: 31628016. doi:10.1016/S1470-2045(19)30532-7.
9. Kusamura S, Cinquini M, Morris D, et al. Multisocietal Consensus on the Use of Cytoreductive Surgery and HIPEC for the Treatment of Diffuse Malignant Peritoneal Mesothelioma: A GRADE Approach for Evidence Evaluation and Recommendation. J Surg Oncol. 2025;131(5):810–815. PMID: 39609952. doi:10.1002/jso.27947.
10. Brown LM, Wilkins SG, Bansal VV, et al. Consensus Guideline for the Management of Peritoneal Mesothelioma. Annals of Surgical Oncology. 2026;33(6):5125–5141. PMID: 40560500. doi:10.1245/s10434-025-17358-x.
11. McGehee E, Gerber DE, Reisch J, Dowell JE. Treatment and Outcomes of Primary Pericardial Mesothelioma: A Contemporary Review of 103 Published Cases. Clinical Lung Cancer. 2019;20(2):e152–e157. PMID: 30594459. doi:10.1016/j.cllc.2018.11.008.
12. Grogg JB, Fronzaroli JN, Oliveira P, et al. Clinicopathological characteristics and outcomes in men with mesothelioma of the tunica vaginalis testis: analysis of published case-series data. Journal of Cancer Research and Clinical Oncology. 2021;147(9):2671–2679. PMID: 33559739. doi:10.1007/s00432-021-03533-6.
13. U.S. Food and Drug Administration. OPDIVO (nivolumab) with YERVOY (ipilimumab): first-line treatment of adult patients with unresectable malignant pleural mesothelioma; marketing approval October 2, 2020. View source.
14. Szlosarek PW, Creelan BC, Sarkodie T, et al. Pegargiminase Plus First-Line Chemotherapy in Patients With Nonepithelioid Pleural Mesothelioma: The ATOMIC-Meso Randomized Clinical Trial. JAMA Oncol. 2024;10(4):475–483. PMID: 38358753. PMCID: PMC10870227. doi:10.1001/jamaoncol.2023.6789.
15. Anagnostou VE, Nowak AK, Brown C, et al. Translational analyses from the randomized phase 3 DREAM3R trial: DuRvalumab with chEmotherapy as first-line treAtment in advanced pleural Mesothelioma. Cancer Res. 2026;86(8 Suppl):Abstract LB105.